Baupost Group LLC MA Buys 440,552 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Baupost Group LLC MA grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 52.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,274,248 shares of the specialty pharmaceutical company’s stock after acquiring an additional 440,552 shares during the period. Jazz Pharmaceuticals accounts for 3.7% of Baupost Group LLC MA’s holdings, making the stock its 9th largest position. Baupost Group LLC MA owned about 2.02% of Jazz Pharmaceuticals worth $136,000,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Jazz Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares during the period. LSV Asset Management increased its position in Jazz Pharmaceuticals by 4.2% during the 2nd quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock worth $264,750,000 after buying an additional 99,705 shares during the period. Pacer Advisors Inc. increased its position in Jazz Pharmaceuticals by 40.7% during the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after buying an additional 527,187 shares during the period. Capital World Investors acquired a new stake in shares of Jazz Pharmaceuticals during the first quarter worth $171,943,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Jazz Pharmaceuticals by 48.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock valued at $130,447,000 after acquiring an additional 398,549 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ JAZZ opened at $110.76 on Friday. The company has a market cap of $6.98 billion, a price-to-earnings ratio of 22.84, a PEG ratio of 1.31 and a beta of 0.57. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $137.38. The stock has a 50-day moving average price of $110.79 and a two-hundred day moving average price of $111.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. As a group, analysts forecast that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on JAZZ shares. Robert W. Baird lowered their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Piper Sandler cut their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. Finally, Morgan Stanley dropped their price objective on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a report on Friday, July 12th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $173.07.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.